LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD (Nasdaq: LFMD) has rescheduled its third quarter 2026 earnings release and conference call to November 12, 2026.
The company expects to issue its earnings release at approximately 4:05 p.m. Eastern time, followed by the conference call at 4:30 p.m. Eastern time. A live and archived webcast will be available.
LifeMD (LFMD) announced an arrangement with Eli Lilly enabling its affiliated pharmacy to dispense and ship self-pay GLP-1 medicines nationwide. The program includes Zepbound (tirzepatide) and Foundayo (orforglipron) at Lilly's established self-pay prices.
Eligible patients can purchase prescribed medicines through LifeMD after an affiliated healthcare provider independently determines treatment is clinically appropriate following a medical evaluation. LifeMD's licensed mail-order pharmacy fulfills and ships prescriptions. The medicines are offered on a cash-pay basis and are not billed to insurance.
LifeMD (Nasdaq: LFMD) will report its third-quarter 2026 financial results before U.S. financial markets open on November 9, 2026.
The results will cover the three and nine months ended September 30, 2026. A conference call will begin at 8:30 a.m. Eastern time that day, with a live and archived webcast available.
LifeMD (LFMD) declared a quarterly cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) of $0.5546875 per share.
The dividend is payable on October 15, 2026 to preferred shareholders of record as of the close of business on October 2, 2026, as authorized by the company’s Board of Directors.
AT&T (T) announced an exclusive collaboration with LifeMD (LFMD)/b) giving eligible wireless and fiber customers a complimentary LifeMD membership, normally $19 per month, through its &More program.The waived membership fee, valued at $228 per year, offers more than 100 million eligible AT&T customers access to LifeMD’s nationwide virtual care and pharmacy platform. Services include virtual primary and 24/7 urgent care, chronic condition management, weight management with GLP‑1 medications, women’s and men’s health, dermatology, and lab services, with many medications shipped directly from LifeMD’s pharmacy.
Enrollment is required, 29 million customers in 11 states gain access first, and additional markets are expected to join in January 2027.
LifeMD (Nasdaq: LFMD) reported second quarter 2026 revenue of $47.3 million, within guidance of $47–$50 million but down from $49.0 million a year earlier. Adjusted EBITDA was a loss of about $3.5 million, versus positive $3.9 million in Q2 2025, though it improved roughly 21% sequentially. Gross margin expanded about 280 basis points year-over-year to approximately 89%, helped by lower shipping and fulfillment costs and scaling of the in-house pharmacy.
Active subscribers grew 20% to about 356,000, including roughly 108,000 Weight Management Program subscribers, and about 84% of revenue came from recurring subscriptions. LifeMD ended the quarter with $25.1 million in cash, no debt, and an undrawn $30 million revolver. The company revised 2026 guidance to revenue of $205.5–$212.5 million and adjusted EBITDA of -$6.0 million to breakeven, versus prior guidance of $220–$230 million and $12–$17 million, but continues to target a Q4 2026 annualized exit run rate of about $250 million of revenue and roughly $22 million of annualized adjusted EBITDA.
LifeMD (Nasdaq: LFMD) reported Q2 2026 revenue of $47.3 million, down from $49.0 million but within guidance, and an adjusted EBITDA loss of about $3.5 million, a ~21% sequential improvement. Gross margin expanded ~280 basis points year-over-year to ~89%, with about 84% of revenue from recurring subscriptions.
Active subscribers rose 20% year-over-year to ~356,000, including ~108,000 Weight Management Program subscribers, as ~95% of new weight management patients began branded GLP-1 therapies. LifeMD ended the quarter with $25.1 million in cash, no debt, and $30 million of undrawn revolver capacity. The company cut full-year 2026 guidance to $205.5–$212.5 million revenue and adjusted EBITDA of negative $6.0 million to breakeven, but still targets a Q4 2026 annualized exit run rate of about $250 million revenue and roughly $22 million of annualized adjusted EBITDA before estimated XYOSTED launch costs.
LifeMD (Nasdaq: LFMD) plans to report financial results for the three and six months ended June 30, 2026, after the U.S. market close on Wednesday, August 5, 2026. The company will host a conference call at 4:30 p.m. Eastern time to discuss its second quarter 2026 results.
Investors can join via toll-free dial-in at (800) 715-9871, international dial-in at +1 (646) 307-1963, using Conference ID 3616168 (“LifeMD, Inc. Second Quarter 2026 Results”). A live and archived webcast will be accessible via the specified link, and participants may also select a “Dial-Me In” option online.
LifeMD (Nasdaq: LFMD) declared a quarterly cash dividend on its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP). The dividend is $0.5546875 per share, payable on July 15, 2026, to shareholders of record as of July 3, 2026.
LifeMD (Nasdaq: LFMD) announced an exclusive telehealth co-marketing collaboration with Halozyme’s Antares Pharma to launch a direct-to-patient, self-pay program for XYOSTED (testosterone enanthate) injection in July 2026.
The program will initially operate in 37 states, offering virtual evaluation, lab-based diagnosis, and home delivery of the once-weekly, FDA-approved testosterone auto-injector for about $249 per month, including medication and clinical care without insurance.